CDRH Compliance Office Seeks Inroads With FDA Office Of Regulatory Affairs
This article was originally published in The Gray Sheet
Executive Summary
The top near-term contribution of the Office of Compliance to CDRH's postmarket reform effort will be trying to improve its working relationship with FDA's Office of Regulatory Affairs
You may also be interested in...
CDRH Unveils Postmarket Safety “Action Items”
FDA's plan to strengthen postmarket device safety by making better use of postmarket data includes modifying its organizational infrastructure, updating adverse event reporting practices and potentially increasing the use of fines for certain types of industry noncompliance
FDA Will Customize Foreign Facility Inspections To Improve Efficiency
FDA inspectors will take a more customized approach to auditing foreign device manufacturing facilities in 2006 to improve the efficiency of costly overseas trips, device center Office of Compliance Director Tim Ulatowski suggests
OC FY 2005 Priorities: MDUFMA, Bioterror, Closing Out Enforcement Actions
Fiscal 2005 marks the inaugural year for the CDRH Office of Compliance's new inspection planning process, an initiative that reflects FDA's emphasis on risk-based regulation